Roth Capital Believes ICUI Won’t Stop Here

By Ryan Adsit

Roth Capital analyst Chris Lewis reiterated a Buy rating on ICU Medical (NASDAQ: ICUI) today and set a price target of $160. The company’s shares opened today at $154.25, close to its 52-week high of $154.80.

According to, Lewis is a 4-star analyst with an average return of 3.7% and a 54.8% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Natus Medical Inc.

ICU Medical has an analyst consensus of Moderate Buy, with a price target consensus of $160.

Based on ICU Medical’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $97.11 million and quarterly net profit of $18.81 million. In comparison, last year the company earned revenue of $86.02 million and had a net profit of $16.27 million.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2016, Vivek Jain, the Chairman & CEO of ICUI sold 7,268 shares for a total of $902,976.

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy, oncology and critical care applications. It operates through the following segments: Infusion Therapy, Critical Care, and Oncology. The Infusion Therapy segment provides needlefree connector products, custom infusion sets, and Tego, a neddlefree hemodialysis connector. The Critical Care segment offers: hemodynamic monitoring systems; closed blood sampling and conservation systems; and other critical care products and accessories. The Oncology segment sells ChemoLock CSTD and components; ChemoClave CSTD and components; and Diana hazardous drug compounding systems. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.